Methoxsalen
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00553 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | localized pagetoid reticulosis | KG + DL |
| 2 | indolent primary cutaneous T-cell lymphoma | KG + DL |
| 3 | neoplasm of mature B-cells | KG + DL |
| 4 | small intestinal Burkitt lymphoma | KG + DL |
| 5 | thyroid gland mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 6 | small intestinal mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 7 | follicular lymphoma, susceptibility to, 1 | KG + DL |
| 8 | breast mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 9 | tonsillar lymphoma | KG + DL |
| 10 | vulvar inverted follicular keratosis | KG + DL |
| 11 | seborrheic keratosis | KG + DL |
| 12 | mycosis fungoides and variants | KG + DL |
| 13 | lymphosarcoma | KG + DL |
| 14 | granulomatous slack skin disease | KG + DL |
| 15 | follicular lymphoma | KG + DL |
| 16 | precursor T-cell acute lymphoblastic leukemia | KG + DL |
| 17 | B-cell neoplasm | KG + DL |
| 18 | Sezary syndrome | KG + DL |
| 19 | primary cutaneous B-cell lymphoma | KG + DL |
| 20 | gastric mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 21 | lymph node cancer | KG + DL |
| 22 | lymphoma | KG + DL |
| 23 | folliculotropic mycosis fungoides | KG + DL |
| 24 | malignant breast phyllodes tumor | KG + DL |
| 25 | interdigitating dendritic cell sarcoma | KG + DL |
| 26 | reticulum cell sarcoma | KG + DL |
| 27 | lymphoma, non-Hodgkin, familial | KG + DL |
| 28 | subcutaneous panniculitis-like T-cell lymphoma | KG + DL |
| 29 | intravascular large B-cell lymphoma | KG + DL |
| 30 | T-cell/histiocyte rich large B cell lymphoma | KG + DL |
| 31 | acute lymphoblastic leukemia (disease) | KG + DL |
| 32 | seborrheic dermatitis | KG + DL |
| 33 | primary organ-specific lymphoma | KG + DL |
| 34 | acute biphenotypic leukemia | KG + DL |
| 35 | Langerhans cell histiocytosis | KG + DL |
| 36 | high grade B-cell lymphoma | KG + DL |
| 37 | gastric diffuse large B-cell lymphoma | KG + DL |
| 38 | lymphomatoid granulomatosis | KG + DL |
| 39 | lymphoblastic leukemia, acute, with lymphomatous features | KG + DL |
| 40 | neoplasm of immature B and T cells | KG + DL |
| 41 | composite lymphoma | KG + DL |
| 42 | ovarian lymphoma | KG + DL |
| 43 | progressive transformation of germinal centers | KG + DL |
| 44 | AIDS-related primary central nervous system lymphoma | KG + DL |
| 45 | nasal cavity lymphoma | KG + DL |
| 46 | colon adenocarcinoma | KG + DL |
| 47 | thyroid gland diffuse large B-cell lymphoma | KG + DL |
| 48 | primary pulmonary diffuse large B-cell lymphoma | KG + DL |
| 49 | primary cutaneous diffuse large B-cell lymphoma, Leg type | KG + DL |
| 50 | small intestinal diffuse large B-cell lymphoma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.